What is asthma?COPD overlap syndrome? Towards a consensus definition from a round table discussion

European Respiratory Journal

Volumn 48, Issue 3, 2016, Pages 664-673

  Sin, Don D ^a   Miravitlles, Marc ^b   Mannino, David M ^c   Soriano, Joan B ^d   Price, David ^e,f   Celli, Bartolome R ^g   Leung, Janice M ^a   Nakano, Yasutaka ^h   Park, Hye Yun ⁱ   Wark, Peter A ^j   Wechsler, Michael E ^k  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f Research in Real Life   (United Kingdom)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

^j UNIVERSITY OF NEWCASTLE   (Australia)

^k DEPARTMENT OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG;

AGE DISTRIBUTION; AIRWAY OBSTRUCTION; ASTHMA; ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE CLASSIFICATION; ENVIRONMENTAL EXPOSURE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE POLICY; HUMAN; LUNG DISEASE; PATIENT CARE; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; REVIEW; RISK FACTOR; SMOKING; SMOKING HABIT; SPIROMETRY; SYMPTOMATOLOGY; TREATMENT RESPONSE; ADULT; AGED; ALGORITHM; BIOMASS; COMPLICATION; CYTOLOGY; DELPHI STUDY; EOSINOPHIL; EVIDENCE BASED MEDICINE; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONOLOGY; STANDARDS; SYNDROME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ALGORITHMS; ASTHMA; BIOMASS; BRONCHODILATOR AGENTS; DELPHI TECHNIQUE; EOSINOPHILS; EVIDENCE-BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; RISK FACTORS; SMOKING; SPIROMETRY; SYNDROME;

EID: 84986223146     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00436-2016     Document Type: Review

References (86)

1. Gallagher M, Hares T, Spencer J, et al. The nominal group technique: a research tool for general practice? Fam Pract 1993; 10: 76-81.
2. Everett A. Piercing the veil of the future. A review of the Delphi method of research. Prof Nurse 1993; 9: 181-185.
3. Jones Criteria (modified) for guidance in the diagnosis of rheumatic fever; report of the Committee on Standards and Criteria for programs of care. Circulation 1956; 13: 617-620.
4. Ciba Guest Symposium. Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions. Thorax 1959; 286-299.
5. Orie NG. [The relationship between asthma and chronic obstructive and restrictive pulmonary diseases; lessons from the past century]. Ned Tijdschr Geneeskd 2002; 146: 1504-1508.
6. Postma DS, Weiss ST, van den Berge M, et al. Revisiting the Dutch hypothesis. J Allergy Clin Immunol 2015; 136: 521-529.
7. Tam A, Sin DD. Pathobiologic mechanisms of chronic obstructive pulmonary disease. Med Clin North Am 2012; 96: 681-698.
8. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
9. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
10. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
11. Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73: 420-427.
12. Tonnel AB, Perez T, Grosbois JM, et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 301-310.
13. Stempel DA, Raphiou IH, Kram KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med 2016; 374: 1833-1830.
14. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207.
15. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715-1726.
16. Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. J Allergy Clin Immunol 1998; 101: 312-319.
17. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101: 457-463.
18. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700-705.
19. Kuo HP, Yu TR, Yu CT. Hypodense eosinophil number relates to clinical severity, airway hyperresponsiveness and response to inhaled corticosteroids in asthmatic subjects. Eur Respir J 1994; 7: 1452-1459.
20. Hanania NA, Sharafkhaneh A, Celli B, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011; 12: 6.
21. Tashkin DP, Altose MD, Bleecker ER, et al. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis 1992; 145: 301-310.
22. Grootendorst DC, Rabe KF. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 77-87.
23. de Carvalho-Pinto RM, Cukier A, Angelini L, et al. Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med 2012; 106: 47-56.
24. Watson L, Vestbo J, Postma DS, et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med 2004; 98: 1207-1213.
25. Dales RE, Mehdizadeh A, Aaron SD, et al. Sex differences in the clinical presentation and management of airflow obstruction. Eur Respir J 2006; 28: 319-322.
26. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest 2001; 119: 1691-1695.
27. Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011; 139: 752-763.
28. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009; 151: 517-527.
29. White P, Thornton H, Pinnock H, et al. Overtreatment of COPD with inhaled corticosteroids: implications for safety and costs: cross-sectional observational study. PLoS One 2013; 8: e75221.
30. Cosio BG, Soriano JB, Lopez-Campos JL, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest 2016; 149: 45-52.
31. Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): a diagnostic challenge. Respirology 2016; 21: 410-418.
32. Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med 2015; 373: 1241-1249.
33. Barnes PJ. Asthma-COPD overlap. Chest 2016; 149: 7-8.
34. Pavord I, Bush A. Two Lovely Black Eyes; Oh, what a surprise! Thorax 2015; 70: 609-610.
35. Vanfleteren LE, Kocks JW, Stone IS, et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax 2014; 69: 72-79.
36. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47: 410-419.
37. Alshabanat A, Zafari Z, Albanyan O, et al. Asthma and COPD overlap syndrome (ACOS): a systematic review and meta analysis. PLoS One 2015; 10: e0136065.
38. Global Strategy for Asthma Management and the Prevention and the Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma-COPD Overlap Syndrome (ACOS). 2015. Available from www. goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdf Date last accessed: May 28, 2016.
39. Koblizek V, Chlumsky J, Zindr V, et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslov 2013; 157: 189-201.
40. Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012; 48: 331-337.
41. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
42. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
43. Gjevre JA, Hurst TS, Taylor-Gjevre RM, et al. The American Thoracic Society's spirometric criteria alone is inadequate in asthma diagnosis. Can Respir J 2006; 13: 433-437.
44. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664.
45. Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med 2013; 1: 564-573.
46. National Institute for Health and Care Excellence (NICE). Diagnosing and assessing COPD. Available from http://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-disease#path=view%3A/pathways/chronicobstructive-pulmonary-disease/diagnosing-and-assessing-copd.xml&content=view-node%3Anodesdifferentiating-between-copd-and-asthma Date last accessed: May 26, 2016.
47. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010; 376: 803-813.
48. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 693-718.
49. Ezzati M, Hoorn SV, Rodgers A, et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362: 271-280.
50. The Tobacco Atlas. Available from www.tobaccoatlas.org/Date last accessed: May 26, 2016.
51. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin immunol 2004; 114: 40-47.
52. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171: 109-114.
53. Pinkerton KE, Harbaugh M, Han MK, et al. Women and lung disease. Sex differences and global health disparities. Am J Respir Crit Care Med 2015; 192: 11-16.
54. Camp PG, Ramirez-Venegas A, Sansores RH, et al. COPD phenotypes in biomass smoke-versus tobacco smoke-exposed Mexican women. Eur Respir J 2014; 43: 725-734.
55. King MS, Eisenberg R, Newman JH, et al. Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. N Engl J Med 2011; 365: 222-230.
56. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin immunol 2002; 109: 189-194.
57. Covar RA, Strunk R, Zeiger RS, et al. Predictors of remitting, periodic, and persistent childhood asthma. J Allergy Clin Immunol 2010; 125: 359-366.e353.
58. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113: 101-108.
59. Amelink M, de Groot JC, de Nijs SB, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol 2013; 132: 336-341.
60. Jenkins HA, Cherniack R, Szefler SJ, et al. A comparison of the clinical characteristics of children and adults with severe asthma. Chest 2003; 124: 1318-1324.
61. Bauer BA, Reed CE, Yunginger JW, et al. Incidence and outcomes of asthma in the elderly. A population-based study in Rochester, Minnesota. Chest 1997; 111: 303-310.
62. Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372: 1049-1057.
63. Barrecheguren M, Roman-Rodriguez M, Miravitlles M. Is a previous diagnosis of asthma a reliable criterion for asthma-COPD overlap syndrome in a patient with COPD? Int J Chron Obstruct Pulmon Dis 2015; 10: 1745-1752.
64. Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 2012; 7: 283-289.
65. Tamada T, Sugiura H, Takahashi T, et al. Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. Int J Chron Obstruct Pulmon Dis 2015; 10: 2169-2176.
66. Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 2016; 71: 118-125.
67. Hasegawa K, Camargo CA Jr. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology 2015; 21: 761-764.
68. Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in COPD: the Copenhagen General Population Study. Am J Respir Crit Care Med 2016; 193: 965-974.
69. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435-442.
70. Aaron SD, Vandemheen KL, Maltais F, et al. TNFalpha antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax 2013; 68: 142-148.
71. Bafadhel M, Davies L, Calverley PM, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J 2014; 44: 789-791.
72. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 523-525.
73. Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70: 115-120.
74. Park HY, Lee H, Koh WJ, et al. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int J Chron Obstruct Pulmon Dis 2016; 11: 23-30.
75. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
76. Wurst KE, Kelly-Reif K, Bushnell GA, et al. Understanding asthma-chronic obstructive pulmonary disease overlap syndrome. Respir Med 2016; 110: 1-11.
77. Menezes AM, Montes de Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014; 145: 297-304.
78. van Boven JF, Roman-Rodriguez M, Palmer JF, et al. Comorbidome, pattern and impact of asthma-COPD overlap syndrome (ACOS) in real-life. Chest 2016; 149: 1011-1020.
79. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124: 474-481.
80. Suzuki T, Tada Y, Kawata N, et al. Clinical, physiological, and radiological features of asthma-chronic obstructive pulmonary disease overlap syndrome. Int J Chron Obstruct Pulmon Dis 2015; 10: 947-954.
81. de Marco R, Marcon A, Rossi A, et al. Asthma, COPD and overlap syndrome: a longitudinal study in young European adults. Eur Respir J 2015; 46: 671-679.
82. Kim MA, Noh CS, Chang YJ, et al. Asthma and COPD overlap syndrome is associated with increased risk of hospitalisation. Int J Tuberc Lung Dis 2015; 19: 864-869.
83. Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med 2013; 1: e29-e30.
84. Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 191: 758-766.
85. Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014; 44: 341-350.
86. Miravitlles M, Alcazar B, Alvarez FJ, et al. What pulmonologists think about the asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis 2015; 10: 1321-1330.